Background & Objectives: Hepatocellular carcinoma (HCC) leads to high morbidity and mortality. Various models have been proposed for predicting the outcome of patients with HCC. We aim to compare the prognostic abilities of Child-Pugh, MELD, MELD-Na, and ALBI scores for predicting in-hospital mortality of HCC. Methods: We enrolled patients diagnosed with liver cirrhosis and HCC from May 2017 through May 2018. We further divided eligible patients into hepatitis B virus (HBV), patients without ascites, and patients with ascites subgroups. Areas under the characteristic curves (AUCs) were analyzed. Results: A total of 495 patients were included in the study. We collected data on patients at admission. A majority of patients were infected with HBV (91.5%). None of them were complicated with hepatic encephalopathy. Only 14.9% of patients presented with ascites. In the whole population, AUCs with 95% confidence interval (CI) of Child-Pugh, ALBI, MELD, and MELD-Na scores in predicting in-hospital mortality were 0.889 (95% CI: 0.858 - 0.915), 0.849 (95% CI: 0.814 - 0.879), 0.669 (95% CI: 0.626 - 0.711), and 0.721 (95% CI: 0.679 - 0.760), respectively. In the patients without ascites subgroup, Child-Pugh showed better discriminatory ability than ALBI score in predicting in-hospital mortality (P = 0.0002), while there were no significant differences among other comparisons. Conclusions: Child-Pugh and ALBI may be useful predictors for predicting in-hospital mortality in whole patients, in patients with HBV infection, and in patients without ascites. In HCC patients with ascites, MELD-Na may be effective for predicting in-hospital mortality.
References
[1]
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. https://doi.org/10.3322/caac.21492
[2]
Global Burden of Disease Cancer Collaboration, Fitzmaurice, C., Abate, D., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdel-Rahman, O., Abdelalim, A., Abdoli, A., Abdollahpour, I., Abdulle, A.S.M., Abebe, N.D., Abraha, H.N., Abu-Raddad, L.J., Abualhasan, A., Adedeji, I.A., Advani, S.M., Afarideh, M., Afshari, M., Aghaali, M. and Murray, C.J.L. (2019) Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived with Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncology, 5, 1749-1768.
[3]
El-Serag, H.B. (2012) Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma. Gastroenterology, 142, 1264-1273.e1. https://doi.org/10.1053/j.gastro.2011.12.061
[4]
Younossi, Z.M., Blissett, D., Blissett, R., Henry, L., Stepanova, M., Younossi, Y., Racila, A., Hunt, S. and Beckerman, R. (2016) The Economic and Clinical Burden of Nonalcoholic Fatty Liver Disease in the United States and Europe. Hepatology (Baltimore, Md.), 64, 1577-1586. https://doi.org/10.1002/hep.28785
[5]
Younossi, Z.M., Koenig, A.B., Abdelatif, D., Fazel, Y., Henry, L. and Wymer, M. (2016) Global Epidemiology of Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes. Hepatology (Baltimore, Md.), 64, 73-84. https://doi.org/10.1002/hep.28431
[6]
Hassan, M.M., Hwang, L.Y., Hatten, C.J., Swaim, M., Li, D., Abbruzzese, J.L., Beasley, P. and Patt, Y.Z. (2002) Risk Factors for Hepatocellular Carcinoma: Synergism of Alcohol with Viral Hepatitis and Diabetes Mellitus. Hepatology (Baltimore, Md.), 36, 1206-1213. https://doi.org/10.1053/jhep.2002.36780
[7]
Ross, R.K., Yuan, J.M., Yu, M.C., Wogan, G.N., Qian, G.S., Tu, J.T., Groopman, J.D., Gao, Y.T. and Henderson, B.E. (1992) Urinary Aflatoxin Biomarkers and Risk of Hepatocellular Carcinoma. The Lancet (London, England), 339, 943-946. https://doi.org/10.1016/0140-6736(92)91528-G
[8]
Ng, A.W.T., Poon, S.L., Huang, M.N., Lim, J.Q., Boot, A., Yu, W., Suzuki, Y., Thangaraju, S., Ng, C.C.Y., Tan, P., Pang, S.T., Huang, H.Y., Yu, M.C., Lee, P.H., Hsieh, S.Y., Chang, A.Y., Teh, B.T. and Rozen, S.G. (2017) Aristolochic Acids and Their Derivatives Are Widely Implicated in Liver Cancers in Taiwan and throughout Asia. Science Translational Medicine, 9, eaan6446. https://doi.org/10.1126/scitranslmed.aan6446
[9]
Forner, A., Reig, M. and Bruix, J. (2018) Hepatocellular Carcinoma. The Lancet (London, England), 391, 1301-1314. https://doi.org/10.1016/S0140-6736(18)30010-2
[10]
Sheka, A.C., Adeyi, O., Thompson, J., Hameed, B., Crawford, P.A. and Ikramuddin, S. (2020) Nonalcoholic Steatohepatitis: A Review. JAMA, 323, 1175-1183. https://doi.org/10.1001/jama.2020.2298
[11]
Pugh, R.N., Murray-Lyon, I.M., Dawson, J.L., Pietroni, M.C. and Williams, R. (1973) Transection of the Oesophagus for Bleeding Oesophageal Varices. The British Journal of Surgery, 60, 646-649. https://doi.org/10.1002/bjs.1800600817
[12]
Kamath, P.S., Kim, W.R. and Advanced Liver Disease Study Group (2007) The Model for End-Stage Liver Disease (MELD). Hepatology (Baltimore, Md.), 45, 797-805. https://doi.org/10.1002/hep.21563
[13]
Arroyo, V. and Colmenero, J. (2003) Ascites and Hepatorenal Syndrome in Cirrhosis: Pathophysiological Basis of Therapy and Current Management. Journal of Hepatology, 38, S69-S89. https://doi.org/10.1016/S0168-8278(03)00007-2
[14]
Fernández-Esparrach, G., Sánchez-Fueyo, A., Ginès, P., Uriz, J., Quintó, L., Ventura, P.J., Cárdenas, A., Guevara, M., Sort, P., Jiménez, W., Bataller, R., Arroyo, V. and Rodés, J. (2001) A Prognostic Model for Predicting Survival in Cirrhosis with Ascites. Journal of Hepatology, 34, 46-52. https://doi.org/10.1016/S0168-8278(00)00011-8
[15]
Biggins, S.W., Kim, W.R., Terrault, N.A., Saab, S., Balan, V., Schiano, T., Benson, J., Therneau, T., Kremers, W., Wiesner, R., Kamath, P. and Klintmalm, G. (2006) Evidence-Based Incorporation of Serum Sodium Concentration into MELD. Gastroenterology, 130, 1652-1660. https://doi.org/10.1053/j.gastro.2006.02.010
[16]
Luca, A., Angermayr, B., Bertolini, G., Koenig, F., Vizzini, G., Ploner, M., Peck-Radosavljevic, M., Gridelli, B. and Bosch, J. (2007) An Integrated MELD Model Including Serum Sodium and Age Improves the Prediction of Early Mortality in Patients with Cirrhosis. Liver Transplantation, 13, 1174-1180. https://doi.org/10.1002/lt.21197
[17]
Chen, K., Cao, X., Zheng, Y., Xu, M. and Peng, J. (2014) Comparative Study of the MELD-Na and Child-Turcotte-Pugh Scores as Short-Term Prognostic Indicators of Acute-on-Chronic Hepatitis B Liver Failure. Chinese Journal of Hepatology, 22, 801-805. (In Chinese) https://doi.org/10.3760/cma.j.issn.1007-3418.2014.11.001
[18]
Kim, K.M., Shim, S.G., Sinn, D.H., Song, J.E., Kim, B.S. and Kim, H.G. (2020) Child-Pugh, MELD, MELD-Na, and ALBI Scores: Which Liver Function Models Best Predicts Prognosis for HCC Patient with Ascites? Scandinavian Journal of Gastroenterology, 55, 951-957. https://doi.org/10.1080/00365521.2020.1788139
[19]
Huo, T.I., Lin, H.C., Hsia, C.Y., Huang, Y.H., Wu, J.C., Chiang, J.H., Chiou, Y.Y., Lui, W.Y., Lee, P.C. and Lee, S.D. (2008) The MELD-Na Is an Independent Short- and Long-Term Prognostic Predictor for Hepatocellular Carcinoma: A Prospective Survey. Digestive and Liver Disease, 40, 882-889. https://doi.org/10.1016/j.dld.2008.01.015
[20]
Ahmed, R., Santhanam, P. and Rayyan, Y. (2015) MELD-Na as a Prognostic Indicator of 30- and 90-Day Mortality in Patients with End-Stage Liver Disease after Creation of Transjugular Intrahepatic Portosystemic Shunt. European Journal of Gastroenterology & Hepatology, 27, 1226-1227. https://doi.org/10.1097/MEG.0000000000000412
[21]
Pozo-Laderas, J.C., Rodríguez-Perálvarez, M., Muñoz-Villanueva, M.C., Rivera-Espinar, F., Durban-García, I., Muñoz-Trujillo, J., Robles-Arista, J.C. and Briceño-Delgado, J. (2019) Pretransplant Predictors of Early Mortality in Adult Recipients of Liver Transplantation in the MELD-Na Era. Predictores Pretrasplante de Mortalidad Precoz en Receptores Adultos de Trasplante Hepático en la era MELD-Na. Medicina Intensiva, 43, 261-269. https://doi.org/10.1016/j.medin.2018.03.008
[22]
Wong, V.W., Chim, A.M., Wong, G.L., Sung, J.J. and Chan, H.L. (2007) Performance of the New MELD-Na Score in Predicting 3-Month and 1-Year Mortality in Chinese Patients with Chronic Hepatitis B. Liver Transplantation, 13, 1228-1235. https://doi.org/10.1002/lt.21222
[23]
Johnson, P.J., Berhane, S., Kagebayashi, C., Satomura, S., Teng, M., Reeves, H.L., O'Beirne, J., Fox, R., Skowronska, A., Palmer, D., Yeo, W., Mo, F., Lai, P., Iñarrairaegui, M., Chan, S.L., Sangro, B., Miksad, R., Tada, T., Kumada, T. and Toyoda, H. (2015) Assessment of Liver Function in Patients with Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade. Journal of Clinical Oncology, 33, 550-558. https://doi.org/10.1200/JCO.2014.57.9151
[24]
Wang, J., Zhang, Z., Yan, X., Li, M., Xia, J., Liu, Y., Chen, Y., Jia, B., Zhu, L., Zhu, C., Huang, R. and Wu, C. (2019) Albumin-Bilirubin (ALBI) as an Accurate and Simple Prognostic Score for Chronic Hepatitis B-Related Liver Cirrhosis. Digestive and Liver Disease, 51, 1172-1178. https://doi.org/10.1016/j.dld.2019.01.011
[25]
Chen, B. and Lin, S. (2017) Albumin-Bilirubin (ALBI) Score at Admission Predicts Possible Outcomes in Patients with Acute-on-Chronic Liver Failure. Medicine, 96, e7142. https://doi.org/10.1097/MD.0000000000007142
[26]
Fragaki, M., Sifaki-Pistolla, D., Orfanoudaki, E. and Kouroumalis, E. (2019) Comparative Evaluation of ALBI, MELD, and Child-Pugh Scores in Prognosis of Cirrhosis: Is ALBI the New Alternative? Annals of Gastroenterology, 32, 626-632. https://doi.org/10.20524/aog.2019.0417
[27]
Peng, Y., Qi, X., Tang, S., Deng, H., Li, J., Ning, Z., Dai, J., Hou, F., Zhao, J., Wang, R. and Guo, X. (2016) Child-Pugh, MELD, and ALBI Scores for Predicting the In-Hospital Mortality in Cirrhotic Patients with Acute-on-Chronic Liver Failure. Expert Review of Gastroenterology & Hepatology, 10, 971-980. https://doi.org/10.1080/17474124.2016.1177788
[28]
Bossuyt, P.M., Reitsma, J.B., Bruns, D.E., Gatsonis, C.A., Glasziou, P.P., Irwig, L., Lijmer, J.G., Moher, D., Rennie, D., de Vet, H.C., Kressel, H.Y., Rifai, N., Golub, R.M., Altman, D.G., Hooft, L., Korevaar, D.A., Cohen, J.F. and STARD Group (2015) STARD 2015: An Updated List of Essential Items for Reporting Diagnostic Accuracy Studies. Clinical Chemistry, 61, 1446-1452. https://doi.org/10.1373/clinchem.2015.246280
[29]
Llovet, J.M., Brú, C. and Bruix, J. (1999) Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification. Seminars in Liver Disease, 19, 329-338. https://doi.org/10.1055/s-2007-1007122
[30]
European Association for the Study of the Liver and European Organisation for Research and Treatment of Cancer (2012) EASL-EORTC Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. Journal of Hepatology, 56, 908-943. https://doi.org/10.1016/j.jhep.2011.12.001
[31]
Ji, J., Wang, H., Li, Y., Zheng, L., Yin, Y., Zou, Z., Zhou, F., Zhou, W., Shen, F. and Gao, C. (2016) Diagnostic Evaluation of Des-Gamma-Carboxy Prothrombin versus α-Fetoprotein for Hepatitis B Virus-Related Hepatocellular Carcinoma in China: A Large-Scale, Multicentre Study. PLOS ONE, 11, e0153227. https://doi.org/10.1371/journal.pone.0153227
[32]
Ke, M.Y., Wu, X.N., Zhang, Y., Wang, S., Lv, Y. and Dong, J. (2019) Serum GP73 Predicts Posthepatectomy Outcomes in Patients with Hepatocellular Carcinoma. Journal of Translational Medicine, 17, Article No. 140. https://doi.org/10.1186/s12967-019-1889-0
[33]
Zhao, S., Wang, M., Yang, Z., Tan, K., Zheng, D., Du, X. and Liu, L. (2020) Comparison between Child-Pugh Score and Albumin-Bilirubin Grade in the Prognosis of Patients with HCC after Liver Resection Using Time-Dependent ROC. Annals of Translational Medicine, 8, 539. https://doi.org/10.21037/atm.2020.02.85
[34]
Zhao, S., Zhang, T., Li, H., Wang, M., Xu, K., Zheng, D., Du, X. and Liu, L. (2020) Comparison of Albumin-Bilirubin Grade versus Child-Pugh Score in Predicting the Outcome of Transarterial Chemoembolization for Hepatocellular Carcinoma Using Time-Dependent ROC. Annals of Translational Medicine, 8, 538. https://doi.org/10.21037/atm.2020.02.124
[35]
Hiraoka, A., Kumada, T., Kudo, M., Hirooka, M., Tsuji, K., Itobayashi, E., Kariyama, K., Ishikawa, T., Tajiri, K., Ochi, H., Tada, T., Toyoda, H., Nouso, K., Joko, K., Kawasaki, H., Hiasa, Y., Michitaka, K. and Real-Life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (Hepatocellular Carcinoma Experts from 48 Clinics) (2017) Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications. Liver Cancer, 6, 204-215. https://doi.org/10.1159/000452846
[36]
Schütte, K., Tippelt, B., Schulz, C., Röhl, F.W., Feneberg, A., Seidensticker, R., Arend, J. and Malfertheiner, P. (2015) Malnutrition Is a Prognostic Factor in Patients with Hepatocellular Carcinoma (HCC). Clinical Nutrition (Edinburgh, Scotland), 34, 1122-1127. https://doi.org/10.1016/j.clnu.2014.11.007
[37]
Liu, P.H., Hsu, C.Y., Hsia, C.Y., Lee, Y.H., Chiou, Y.Y., Huang, Y.H., Lee, F.Y., Lin, H.C., Hou, M.C. and Huo, T.I. (2017) ALBI and PALBI Grade Predict Survival for HCC across Treatment Modalities and BCLC Stages in the MELD Era. Journal of Gastroenterology and Hepatology, 32, 879-886. https://doi.org/10.1111/jgh.13608
[38]
Chen, H., Hu, N., Chang, P., Kang, T., Han, S., Lu, Y. and Li, M. (2017) Modified Glasgow Prognostic Score Might Be a Prognostic Factor for Hepatocellular Carcinoma: A Meta-Analysis. Panminerva Medica, 59, 302-307. https://doi.org/10.23736/S0031-0808.16.03236-5
[39]
Casadei-Gardini, A., Dadduzio, V., Rovesti, G., Cabibbo, G., Vukotic, R., Rizzato, M.D., Orsi, G., Rossi, M., Guarneri, V., Lonardi, S., D’agostino, D., Celsa, C., Andreone, P., Zagonel, V., Scartozzi, M., Cascinu, S. and Cucchetti, A. (2020) Utility of Neutrophil-to-Lymphocyte Ratio to Identify Long-Term Survivors among HCC Patients Treated with Sorafenib. Medicine, 99, e19958. https://doi.org/10.1097/MD.0000000000019958
